Search / Trial NCT06225882

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

Launched by HOSPICES CIVILS DE LYON · Jan 17, 2024

Trial Information

Current as of October 03, 2024

Recruiting

Keywords

Lumarisan Primary Hyperoxaluria Type 1 (Ph1) Retrospective And Prospective Data.

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patient with primary hyperoxaluria type 1 who has been treated with Lumasiran, since the beginning of the ATU (temporary authorization for use) and in post-marketing.
  • Exclusion Criteria:
  • * Opposition of the patient or his legal representatives for minors.
  • * Not covered by social security.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Besançon, , France

Lyon, , France

Bron, , France

Paris, Ile De France, France

Paris, , France

Marseille, , France

Paris, , France

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0